Cancer and patients with end-stage renal failure Recipients of renal transplants may acquire cancer by the accidental transplantation of cancer cells with a kidney taken from donors with cancer, by the growth of residual or metastatic tumour in patients with pre-existing malignancy, or by the de-novo formation of neoplasms some time after transplantation.'
Recipients of renal transplants may acquire cancer by the accidental transplantation of cancer cells with a kidney taken from donors with cancer, by the growth of residual or metastatic tumour in patients with pre-existing malignancy, or by the de-novo formation of neoplasms some time after transplantation. ' An increased incidence of de-novo neoplasms has been reported1 2 in patients after renal transplantation, and the main factor responsible is thought to be the prolonged use of immunosuppressive drugs given to prevent rejection. Penn and Starzll reported 75 long-term survivors of organ transplantation who had developed de-novo neoplasms, including 16 of their own patients. The incidence of neoplasia was 80 times greater than in the average population in a comparable age range. Forty-four of the patients had epithelial tumours, including squamous-cell or basal-cell skin carcinoma (11 cases), in-situ carcinoma of the cervix uteri (eight cases), carcinoma of the lip (eight cases), and a variety of other tumours. Thirtytwo mesenchymal tumours occurred in 31 patients, including 28 lymphomas. There were 21 patients with reticulum-cell sarcoma. Out of 27 patients with lymphoma, 14 The data on the increased incidence of malignancy in uraemic patients have been criticised as inconclusive. The reports from the National7 and European Dialysis Registries8 have been said to be inadequate because non-fatal cases were not reported and the length of exposure to uraemia and size of the population at risk were unknown.9 Lindner et al9 therefore studied 153 patients who had had long-term dialysis for an average of 66 months to determine the incidence and type of neoplasms and to compare these findings with cancer rates for the population in the same geographical area. Nine cancers were found among 148 men (six lung, one kidney, one pancreas, one carcinoid). Eight of the nine men were smokers. This result was higher than expected (that is, 3-6 cases; p <0 0137) for exposure-specific and age-specific controls of the same sex.
The increase in the incidence of common tumours supports the findings of Matas et More recently a much larger controlled trial of sodium cromoglycate (800 mg daily) failed to confirm these early findings; similar numbers of patients with symptomatic ulcerative colitis at the start of the trial improved, deteriorated, or maintained a steady state in both the treatment and placebo groups.3 The number of relapses among those patients who were in remission at the start of the trial was also similar in the treatment and placebo groups. In a separate study patients with ulcerative colitis in remission were allocated at random to receive either a low-dose or high-dose sodium cromoglycate regimen or sulphasalazine. The relapse rate was similar in the two groups receiving sodium cromoglycate, which proved considerably less effective than sulphasalazine in maintaining remission.4 5 The evidence from relapse rates in these trials4 5 suggests that sodium cromoglycate is little more effective than placebo treatment-but this view has now been challenged in a recent study where the relapse rate for patients taking sodium cromoglycate was 4000 compared with 75% in the placebo group.6 There is, however, general agreement that the addition of sodium cromoglycate to conventional treatment confers no additional benefit.6 7 The place of sodium cromoglycate in ulcerative colitis seems limited. It may be worth trying in symptomatic patients who cannot tolerate sulphasalazine, though even in this group of patients evidence for its value is conflicting. Desensitisation is probably a more effective and practical approach for patients with sulphasalazine intolerance8-and an encouraging prospect is on the horizon with tests of a new agent comprising two molecules of 5-aminosalicylate, the active component of sulphasalazine, from which sulphapyridine (which is responsible for sulphasalazine intolerance) has been eliminated.9
